Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lu 177 edotreotide - ITM Solucin

Next Previous
Drug Profile

Lu 177 edotreotide - ITM Solucin

Alternative Names: 177Lu-DOTATOC; 177Lu-Edo; 177Lu-edotreotide; 177Lu-edotreotide PRRT; DP-1111; ITM-11; Lutetium 177 Edotreotide; Lutetium-177 labelled edotreotide - ITM Solucin; n.c.a.177Lu DOTATOC; n.c.a.177Lu-Edotreotide; Peptide receptor radionuclide therapy (PRRT) with 177Lu-Edotreotide; Solucin; Targeted Radionuclide Therapy with 177Lu-edotreotide

Latest Information Update: 29 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ITM Solucin
  • Class Antineoplastics; Drug conjugates; Peptide drug conjugates; Peptides; Radioisotopes; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroendocrine tumours
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Neuroendocrine tumours

Most Recent Events

  • 26 Jun 2023 ITM Oncologics plans a phase III LEVEL trial for Neuroendocrine tumours (Metastatic disease, Late-stage disease, Second-line therapy or greater, First-line therapy, Inoperable/Unresectable) in France, Italy and Spain (PO) (NCT05918302)
  • 20 Mar 2023 Phase-III clinical trials in Neuroendocrine tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Australia (IV) (NCT04919226)
  • 27 Oct 2022 Lu 177 edotreotide - ITM Solucin receives Fast Track designation for Neuroendocrine tumours [IV,Infusion] in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top